In plain terms: Amla (Indian Gooseberry, Emblica officinalis) has some human trial evidence supporting it, but the evidence is not yet strong enough for EBL to call it established. It is worth knowing about and worth discussing with your clinician.
Amla (Indian Gooseberry, Emblica officinalis)
The evidence as the record states it
Setayesh et al. (Diabetes Metab Syndr, 2023; PMID 36934568): systematic review and meta-analysis of RCTs: Amla supplementation improved lipid profile, glucose, and C-reactive protein in adults. Usharani et al. (BMC Complement Altern Med, 2019; PMID 31060549): randomized double-blind placebo-controlled trial: standardized Phyllanthus emblica extract improved endothelial function, systemic inflammation, and lipid profile in metabolic syndrome. Grade B on lipids; glycemic and CRP effects are more modest (Grade C).
Evidence by specific use
Why Grade B and not Grade A
Grade B reflects moderate human evidence -- typically a single strong trial, multiple smaller trials, or surrogate endpoint data without hard clinical outcome replication. To reach Grade A, Amla (Indian Gooseberry, Emblica officinalis) would require at least one additional independent randomized trial demonstrating a hard clinical endpoint or objectively measured functional outcome in a comparable population.
What this grade covers and what it does not
What would move this grade
An independent randomized trial demonstrating a hard clinical endpoint -- mortality, major adverse event, or objectively confirmed functional improvement -- in an adequately powered sample, with results independently replicated, would support Grade A.